The FDA has approved Wegovy HD, a higher‑dose formulation of Novo Nordisk’s Wegovy (semaglutide), marking the fourth product cleared under its Commissioner’s National Priority Voucher (CNPV) pilot program, which is an accelerated review pathway designed to shorten review timelines for therapies aligned with national health priorities.
It’s yet another win for Novo, as the company recently won approval for a pill version of Wegovy in December.
The newly approved 7.2 mg semaglutide injection, marketed as Wegovy HD, is intended for adults with obesity or adults who are overweight with at least one weight‑related condition, offering significantly greater weight loss than previously approved doses.
Novo Nordisk’s new Wegovy HD delivers a dose well above the previous maximum maintenance level of 2.4 mg.
The higher-strength injection is approved for use in conjunction with increased physical activity and a reduced-calorie diet for patients who have tolerated the 2.4 mg dose for at least four weeks but still need additional weight loss.
In the STEP UP Phase III trial, which included 1,407 adults with obesity who did not have diabetes, once‑weekly semaglutide 7.2 mg led to a mean weight reduction of 20.7% after 72 weeks. In comparison, patients on the previous highest 2.4 mg dose saw a 17.5% reduction, while the placebo group experienced a 2.4% decrease.
About one third of patients on 7.2 mg achieved weight loss of 25% or more, nearly double the rate of the 2.4 mg group, while no control patients reached this level.
In adults with obesity and type 2 diabetes, the higher dose demonstrated a mean weight loss of 14.1%, while blood sugar-lowering effects (A1C reduction) were similar to those seen with the lower 2.4 mg dose.
The efficacy data assumes perfect adherence to the dosing schedule, referred to as an efficacy estimand, but Novo also reported results using a broader treatment regimen accounting for missed doses or additional weight-loss medications. In this analysis, patients on the 7.2 mg dose lost an average of 18.8% of their body weight, compared with 15.5% for the 2.4 mg dose and 3.9% for placebo.
The CNPV pilot program, which debuted in June 2025, aims to accelerate FDA decisions from the typical 10- to 12-month timeline to as little as one to two months for selected products that address critical public health needs, such as innovative therapies for widespread diseases or unmet medical needs.
Wegovy HD’s approval, completed just 54 days after filing, highlights the speed of the pathway.
While clinicians and patients may welcome the prospect of a higher-efficacy option in obesity treatment, the safety profile remains consistent with established GLP‑1 receptor agonist effects, including predominantly gastrointestinal side effects and some reports of altered skin sensation that are under continued FDA review.
Novo Nordisk plans to launch Wegovy HD in April, with US pricing to be announced at that time. The higher dose will be available through all existing Wegovy channels, including traditional pharmacies, select telehealth providers such as GoodRx, and Novo’s own NovoCare Pharmacy.
The company is working to reclaim its leadership in the US obesity market after losing ground to Eli Lilly and its rival drug Zepbound (tirzepatide). Early 2026 has signaled some momentum, with the launch of the oral version of Wegovy that has outpaced the initial uptake of both injectable Wegovy and Zepbound.
Despite this, Novo Nordisk has forecasted a 5% to 13% sales decline for 2026, despite its new Wegovy offerings, owing to an intensely competitive and high-stakes weight loss market.
Join or login to leave a comment
JOIN LOGIN